ReviewOcular immunology and inflammation2010
Influence of immune privilege on ocular tumor development.
Review in Ocular immunology and inflammation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites.Molecular biology reports · 2025Review
- Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy.Veterinary sciences · 2025Review
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- NFrontiers in oncology · 2021Article
- Update onCancers · 2020Review
- Article
- Uveal melanoma: progress in molecular biology and therapeutics.Therapeutic advances in medical oncology · 2020Review
- Differential modulation and prognostic values of immune-escape genes in uveal melanoma.PloS one · 2019Article
- Abnormally expressed JunB transactivated by IL-6/STAT3 signaling promotes uveal melanoma aggressiveness via epithelial-mesenchymal transition.Bioscience reports · 2018Article
- Focus on cutaneous and uveal melanoma specificities.Genes & development · 2017Review
- The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanomaTheranostics · 2017Article
- Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Comment on: 'guidelines for the use of cell lines in biomedical research': human-to-human cancer transmission as a laboratory safety concern.British journal of cancer · 2015Article
- Biology of advanced uveal melanoma and next steps for clinical therapeutics.Pigment cell & melanoma research · 2015Review
- Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.Cancer immunology research · 2014Article
- In this issue: Immunology of the eye--inside and out.International reviews of immunology · 2013Article
- Ascorbate in aqueous humor augments nitric oxide production by macrophages.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Epigenetic regulation of CXCR4 expression by the ocular microenvironment.Investigative ophthalmology & visual science · 2013Article
- Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.Cancer immunology, immunotherapy : CII · 2012Article
- Good news-bad news: the Yin and Yang of immune privilege in the eye.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Mechanisms that maintain ocular immune privilege may contribute to ocular tumor progression by inhibiting tumoricidal immune responses. Consistent with that notion are observations from transplantable tumor models in mice demonstrating that the tumoricidal activity of CD8(+) cytolytic T lymphocytes (CTL) may be inhibited directly by interfering with CTL effector function in the eye or indirectly by abrogating the effector function of CD8+ T cell-activated intratumoral macrophages that are critical for ocular tumor rejection. In addition, epigenetic gene regulation by factors within the ocular tumor environment favors the generation of tumor variants that are resistant to CD8(+) CTL. Intratumoral macrophages may be essential for eliminating these variants because, unlike CTL, their tumoricidal activity is nonspecific. Hence, the inhibition of macrophage effector function within the eye, presumably to preserve immune privilege by minimizing ocular immunopathology, may hasten the outgrowth of tumor escape variants which contributes to ocular tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.